MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-01-2024
Bausch Health Companies Net Income 2011-2026 | BHC
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Bausch Health Companies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -592 M | -225 M | -948 M | -560 M | -1.79 B | -4.15 B | 2.4 B | -2.41 B | -292 M | 914 M | -866 M | -116 M | 160 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.4 B | -4.15 B | -651 M |
Quarterly Net Income Bausch Health Companies
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 M | -64 M | - | -378 M | 26 M | -201 M | - | 399 M | -145 M | -69 M | - | 188 M | -595 M | -610 M | -153 M | 71 M | -326 M | -152 M | -1.52 B | -48 M | -170 M | -48 M | -344 M | -351 M | -872 M | -2.58 B | 513 M | 1.3 B | -37 M | 629 M | -515 M | -1.22 B | -304 M | -373 M | -385 M | 51.7 M | -51.6 M | 98.5 M | 512 M | 276 M | 122 M | -20.3 M | - | -972 M | 10.8 M | -27.5 M | - | 7.64 M | 232 M | 179 M | - | 183 M | 202 M | 6.48 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.3 B | -2.58 B | -156 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Drug manufacturers industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-14.3 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
-14.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-20.1 M | - | - | $ 142 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-26.5 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-74.8 M | - | - | $ 754 M | USA |
 |
Cronos Group
CRON
|
-73.1 M | $ 2.68 | 0.33 % | $ 1.38 B |  Canada |
 |
DURECT Corporation
DRRX
|
-27.6 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
35.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-2.45 B | - | - | $ 28.9 M |  Irlanda |
 |
Catalent
CTLT
|
-1.04 B | - | - | $ 11.5 B | USA |
 |
Harrow Health
HROW
|
-5.14 M | $ 41.51 | 2.41 % | $ 1.53 B | USA |
 |
Athenex
ATNX
|
-103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.9 M | $ 4.14 | -1.19 % | $ 58.2 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-48.8 M | - | - | $ 2.06 B |  France |
 |
Pacira BioSciences
PCRX
|
-99.6 M | $ 25.04 | -1.77 % | $ 1.16 B | USA |
 |
Jupiter Wellness
JUPW
|
-68.2 M | - | - | $ 33.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-510 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-115 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Solid Biosciences
SLDB
|
-174 M | $ 7.13 | -1.86 % | $ 624 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.46 M | $ 1.15 | 4.55 % | $ 1.43 M | USA |
 |
Evoke Pharma
EVOK
|
-7.79 M | - | - | $ 36.6 M | USA |
 |
Tilray
TLRY
|
-1.45 B | $ 6.13 | -1.76 % | $ 3.79 B | Canada |
 |
Canopy Growth Corporation
CGC
|
-598 M | $ 1.13 | 1.35 % | $ 122 M | Canada |
 |
Veru
VERU
|
-37.8 M | $ 2.26 | 0.44 % | $ 305 M | USA |
 |
Aurora Cannabis
ACB
|
-695 M | $ 3.46 | 0.58 % | $ 86.3 M | Canada |
 |
Lannett Company
LCI
|
-232 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-131 M | $ 1.43 | 1.06 % | $ 402 M | Canada |
 |
Evolus
EOLS
|
-51.6 M | $ 5.36 | -0.65 % | $ 346 M | USA |
 |
Sundial Growers
SNDL
|
-230 M | $ 1.42 | 4.04 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
-760 M | $ 8.32 | 1.09 % | $ 426 M | USA |
 |
Organogenesis Holdings
ORGO
|
861 K | $ 2.44 | 3.83 % | $ 321 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-90.4 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
-153 K | $ 0.82 | -5.79 % | $ 3.54 M | USA |
 |
ProPhase Labs
PRPH
|
18.5 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-70.2 M | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
-30.4 M | $ 18.42 | -0.08 % | $ 118 M | USA |
 |
PetIQ
PETQ
|
2.13 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-57.4 M | $ 7.68 | 2.13 % | $ 303 M | USA |
 |
Recro Pharma
REPH
|
-13.3 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-35.5 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-8.61 M | $ 0.98 | 5.87 % | $ 48.9 M | USA |
 |
PLx Pharma
PLXP
|
-46.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
54.7 M | $ 15.03 | 0.6 % | $ 18 B | USA |
 |
Zomedica Corp.
ZOM
|
-81.9 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-5.31 M | $ 0.87 | -1.19 % | $ 31.3 M | USA |
 |
Tricida
TCDA
|
-177 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.19 M | $ 0.57 | 5.35 % | $ 2.45 M |  China |
 |
TherapeuticsMD
TXMD
|
-569 K | $ 2.05 | 0.25 % | $ 23.7 M | USA |